| Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer F André, E Ciruelos, G Rubovszky, M Campone, S Loibl, HS Rugo, ... New England Journal of Medicine 380 (20), 1929-1940, 2019 | 2087 | 2019 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 693 | 2018 |
| COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets TM Delorey, CGK Ziegler, G Heimberg, R Normand, Y Yang, ... Nature 595 (7865), 107-113, 2021 | 629 | 2021 |
| Convergent loss of PTEN leads to clinical resistance to a PI (3) Kα inhibitor D Juric, P Castel, M Griffith, OL Griffith, HH Won, H Ellis, SH Ebbesen, ... Nature 518 (7538), 240-244, 2015 | 583 | 2015 |
| Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma L Goyal, SK Saha, LY Liu, G Siravegna, I Leshchiner, LG Ahronian, ... Cancer discovery 7 (3), 252-263, 2017 | 469 | 2017 |
| CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors SR Vora, D Juric, N Kim, M Mino-Kenudson, T Huynh, C Costa, ... Cancer cell 26 (1), 136-149, 2014 | 450 | 2014 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 413 | 2019 |
| Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: Final overall survival … F André, EM Ciruelos, D Juric, S Loibl, M Campone, IA Mayer, ... Annals of Oncology 32 (2), 208-217, 2021 | 387 | 2021 |
| Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ... Journal of Clinical Oncology 35 (19), 2141-2148, 2017 | 382 | 2017 |
| Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study D Juric, J Rodon, J Tabernero, F Janku, HA Burris, JHM Schellens, ... Journal of Clinical Oncology 36 (13), 1291-1299, 2018 | 371 | 2018 |
| Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas M Bredel, C Bredel, D Juric, GR Harsh, H Vogel, LD Recht, BI Sikic Cancer research 65 (19), 8679-8689, 2005 | 359 | 2005 |
| A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer IA Mayer, VG Abramson, L Formisano, JM Balko, MV Estrada, ... Clinical cancer research 23 (1), 26-34, 2017 | 341 | 2017 |
| mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 314 | 2013 |
| Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK … N Tanaka, JJ Lin, C Li, MB Ryan, J Zhang, LA Kiedrowski, AG Michel, ... Cancer discovery 11 (8), 1913-1922, 2021 | 310 | 2021 |
| AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas M Elkabets, E Pazarentzos, D Juric, Q Sheng, RA Pelossof, S Brook, ... Cancer cell 27 (4), 533-546, 2015 | 310 | 2015 |
| TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma L Goyal, L Shi, LY Liu, F Fece de la Cruz, JK Lennerz, S Raghavan, ... Cancer discovery 9 (8), 1064-1079, 2019 | 292 | 2019 |
| CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ... Cell reports 17 (9), 2367-2381, 2016 | 272 | 2016 |
| Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open … HS Rugo, F Lerebours, E Ciruelos, P Drullinsky, M Ruiz-Borrego, ... The Lancet Oncology 22 (4), 489-498, 2021 | 240 | 2021 |
| PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 H Ebi, C Costa, AC Faber, M Nishtala, H Kotani, D Juric, P Della Pelle, ... Proceedings of the National Academy of Sciences 110 (52), 21124-21129, 2013 | 238 | 2013 |
| Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor–positive advanced breast cancer: a phase 1b clinical trial D Juric, F Janku, J Rodón, HA Burris, IA Mayer, M Schuler, ... JAMA oncology 5 (2), e184475-e184475, 2019 | 230 | 2019 |
